April 21, 2026 11:20–11:38 AM
Broadway 3
DermiSense develops a low-cost, zero-power, minimally invasive microneedle patch platform that extracts dermal interstitial fluid (ISF) for biomarker analysis.
This innovative technology simplifies diagnostic testing, reduces patient discomfort, and has the potential to replace traditional blood sampling.
